Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM)

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why IMNM stock is a Buy.